摘要
目的探讨思他宁在合并肝炎后肝硬化的肝癌切除术中的应用价值。方法选取该科收治的58例肝硬化并行肝癌切除术的患者随机分组,28例术中至术后72h持续泵注思他宁治疗(观察组),另30例未用任何生长抑素类药物(对照组),观察围手术期情况。结果两组患者均无住院期间死亡。观察组的术中出血及肝门阻断例数比对照组显著减少;术后第3天肝酶水平、胸腹水例数、腹腔管留置时间及住院时间均较对照组明显减少。结论思他宁可明显减少合并肝炎后肝硬化的肝癌切除术中的术中出血,促进肝功能恢复,减少腹水等术后并发症,安全有效,值得临床推广应用。
Objective To investigate the Stilamin with hepatitis cirrhosis of liver cancer resection in value. Methods Undergradu- ate from January 2012 to December parallel treated 58 patients with liver cirrhosis liver cancer resection in patients randomized, 28 cases of surgery to 72 hours after continuous infusion Stilamin treatment（observation group）, and 30 patients did not any the so- matostatin drugs （control group）, observed the perioperative period. Results Two groups of patients had died during hospitalization. Blood loss and liver of the observation group, the door blocking the number of cases significantly reduced compared with the con- trol group; 3 days after liver enzyme levels, the number of cases of pleural effusion, abdominal tube indwelling time and length of hospital stay was significantly reduced compared with the control group. Conclusion Think he would rather significantly reduced blood loss in the combined hepatitis, cirrhosis liver cancer resection, and promote liver function and reduce postoperative compli- cations such as aseites, safe and effective, worthy of clinical application.
出处
《中外医疗》
2013年第21期88-89,共2页
China & Foreign Medical Treatment
基金
广州市科技计划重点项目基金(2011J4100053)
